Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Down 19.7% in March

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the target of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 1,670,000 shares, a decrease of 19.7% from the February 28th total of 2,080,000 shares. Currently, 14.1% of the shares of the stock are sold short. Based on an average daily volume of 526,700 shares, the days-to-cover ratio is currently 3.2 days.

Institutional Investors Weigh In On Jasper Therapeutics

Hedge funds have recently modified their holdings of the stock. Rhumbline Advisers raised its stake in Jasper Therapeutics by 12.6% during the fourth quarter. Rhumbline Advisers now owns 14,761 shares of the company’s stock worth $316,000 after purchasing an additional 1,652 shares during the period. BNP Paribas Financial Markets boosted its holdings in Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after acquiring an additional 1,698 shares during the last quarter. Barclays PLC grew its position in Jasper Therapeutics by 13.6% during the fourth quarter. Barclays PLC now owns 18,334 shares of the company’s stock valued at $392,000 after acquiring an additional 2,188 shares during the period. Wellington Management Group LLP increased its stake in Jasper Therapeutics by 13.9% during the fourth quarter. Wellington Management Group LLP now owns 27,069 shares of the company’s stock worth $579,000 after acquiring an additional 3,310 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of Jasper Therapeutics by 106.7% in the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock valued at $159,000 after purchasing an additional 3,828 shares in the last quarter. 79.85% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on JSPR. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. BMO Capital Markets assumed coverage on Jasper Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $63.00 price target on the stock. Royal Bank of Canada dropped their price objective on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research note on Thursday, January 9th. UBS Group began coverage on Jasper Therapeutics in a research report on Thursday, February 13th. They issued a “buy” rating and a $38.00 price target for the company. Finally, JMP Securities reiterated a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a research report on Monday, January 6th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics presently has an average rating of “Buy” and an average target price of $62.50.

Jasper Therapeutics Stock Performance

JSPR stock opened at $4.46 on Monday. Jasper Therapeutics has a one year low of $4.38 and a one year high of $31.01. The stock has a market capitalization of $67.00 million, a P/E ratio of -0.94 and a beta of 2.23. The company has a 50 day moving average price of $5.69 and a two-hundred day moving average price of $14.72.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.35). Research analysts forecast that Jasper Therapeutics will post -4.47 earnings per share for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.